molecules-logo

Journal Browser

Journal Browser

Recent Progress in Biocatalysis and Enzyme Engineering for Manufacturing Pharmaceutical Intermediates

A special issue of Molecules (ISSN 1420-3049). This special issue belongs to the section "Chemical Biology".

Deadline for manuscript submissions: 31 December 2024 | Viewed by 1274

Special Issue Editor


E-Mail Website
Guest Editor

Special Issue Information

Dear Colleagues,

Biocatalysis is a benign approach to replace and expand traditional organic synthesis due to its high efficiency, excellent selectivity and mild reaction conditions. Enzyme engineering enables one to adapt catalyst to the desired reaction and process. Recently, various strategies to adapt enzymes for use as catalysts for efficient biocatalysis, such as chemical modification, immobilization, site-directed mutagenesis, directed evolution of enzymes, computational design, substrate engineering and medium engineering, have been successfully developed. Novel biocatalysts and bioprocesses have been effectively utilized for the production of value-added pharmaceutical intermediates for human society.

This Special Issue aims to showcase advancements in biocatalysis and enzyme engineering to enhance their efficiency, specificity and stability in a benign bioreaction system. Original research papers and reviews focused on the frontiers of biocatalysis and enzyme engineering are collected in this Special Issue. Other submissions are also welcome from outside the areas presented above.

Prof. Dr. Yu-Cai He
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Molecules is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • biochemical engineering
  • biocatalysis and biotransformation
  • biosynthesis and metabolic engineering
  • bioprocess and biosystem engineering
  • combination catalysis
  • synthetic biology approaches

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.

Further information on MDPI's Special Issue polices can be found here.

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Research

13 pages, 2958 KiB  
Article
Effective Synthesis of mRNA during In Vitro Transcription with Fewer Impurities Produced
by Wei He, Qi Geng, Guiying Ji, Ji Li, Dan Wang, Yucai He, Qiuheng Jin and Jianren Ye
Molecules 2024, 29(19), 4713; https://doi.org/10.3390/molecules29194713 - 5 Oct 2024
Viewed by 1104
Abstract
The remarkable efficacy of COVID-19 vaccines has established mRNA as a highly promising biomedical technology. However, the adequate application of mRNA therapeutics necessitates additional measures to mitigate the inherent immunogenicity, which is predominantly caused by dsRNA. As a byproduct of the in vitro [...] Read more.
The remarkable efficacy of COVID-19 vaccines has established mRNA as a highly promising biomedical technology. However, the adequate application of mRNA therapeutics necessitates additional measures to mitigate the inherent immunogenicity, which is predominantly caused by dsRNA. As a byproduct of the in vitro transcription of mRNA, dsRNA was reported to be originated through several distinct mechanisms, including the extension of 3′ loop-back hairpins, the extension of hybridized abortive transcripts, and promoter-independent transcription. The intricate mechanisms involved pose a dilemma as the reduction in dsRNA results in a concomitant decrease in other critical quality attributes of mRNA. Here, we demonstrate that the promoter binding motifs of T7 RNA polymerase directly impact the production of promoter-independent transcription-based dsRNA. Specifically, the G753A mutation significantly reduces the formation of dsRNA byproducts, which can further combine with modified nucleotides to enhance the effectiveness of dsRNA mitigation and with previously reported high-integrity mutation K389A to minimize side effects. Accordingly, the present study reports a cost-effective approach to synthesize high-purity, less immunostimulatory mRNA by using an engineered T7 RNA polymerase mutant. Full article
Show Figures

Figure 1

Back to TopTop